Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis
Michael P. Pender(The University of Queensland), Rajiv Khanna(QIMR Berghofer Medical Research Institute), Sweera Rehan(QIMR Berghofer Medical Research Institute), Blake T. Aftab(Unknown), Katherine Matthews, Corey Smith(QIMR Berghofer Medical Research Institute), Kerryn A. Green(The University of Queensland), Peter A. Csurhes(The University of Queensland), Alan Coulthard(Mental Health Research Institute), Zara A. Ioannides(The University of Queensland), Kate Thompson(The University of Queensland), Stefan Blum, Andrew Swayne, Scott R. Burrows(QIMR Berghofer Medical Research Institute), Nanette L. Douglas(The University of Queensland), Michelle A. Neller(QIMR Berghofer Medical Research Institute), Kaye D. Hooper(The University of Queensland), Leone Beagley, Tracey Hopkins(Royal Brisbane and Women's Hospital), Pauline Crooks(QIMR Berghofer Medical Research Institute)
Cited by 160
Related Papers
Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke
|New England Journal of Medicine|2018|856
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
|Cancer Discovery|2019|272
Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients.
|Journal of Clinical Pathology|1984|261
A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses
|Proceedings of the National Academy of Sciences|2004|235